Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide ([@b75-btt-2-453]; [@b15-btt-2-453], [@b13-btt-2-453]; [@b7-btt-2-453]; [@b12-btt-2-453]; [@b58-btt-2-453], [@b59-btt-2-453]; [@b32-btt-2-453]; [@b40-btt-2-453]; [@b50-btt-2-453]; [@b91-btt-2-453]) and has been reviewed recently ([@b91-btt-2-453]; [@b14-btt-2-453]; [@b61-btt-2-453]; [@b35-btt-2-453]; [@b53-btt-2-453]). The incidence ranges from \<10 cases per 100,000 population and year in North America and Western Europe to 50--150 cases per 100,000 population and year in parts of Africa and Asia where HCC is responsible for a large proportion of cancer deaths. However, a rise in the incidence of and mortality from HCC, most likely reflecting the high prevalence of hepatitis C virus (HCV) infection, has also been observed in most industrialized countries (Defuffic et al 1998; [@b34-btt-2-453]; [@b32-btt-2-453]; [@b22-btt-2-453]; [@b96-btt-2-453]).

HCC etiologies and risk factors
===============================

The major etiologies of HCC are well defined ([Table 1](#t1-btt-2-453){ref-type="table"}) and include, apart from the well known factors, overweight in men ([@b19-btt-2-453]), non-alcoholic fatty liver disease (NAFLD), and diabetes mellitus ([@b32-btt-2-453]). The HCC risk in patients with liver cirrhosis depends on the activity, duration, and the etiology of the underlying liver disease ([Figure 1](#f1-btt-2-453){ref-type="fig"}). Clinical and biological variables, eg, age, anti-HCV positivity, partial prothrombin time, and platelet count, enable further indentification of a subset of patients with the highest risk of HCC development ([@b97-btt-2-453]). While patients with hepatitis e antigen (HBeAg) positive chronic hepatitis B virus (HBV) have a higher risk of HCC development ([@b102-btt-2-453]) and of early recurrence and poor survival after curative resection (Sun et al 1997) than anti-HBe positive patients, a recent study in Taiwanese patients showed that the HBV DNA concentration in serum (viral load) correlates with the HCC risk, independent of the HBeAg/anti-HBe status and the aspartate aminotransferase or alanine aminotransferase level ([@b25-btt-2-453]). Also, occult (anti-HBc positive only) and past HBV infection (anti-HBc and anti-HBs positive) carry higher HCC risk than healthy individuals ([@b103-btt-2-453]; [@b81-btt-2-453]). For HCV infected patients, recently identified viral risk factors for HCC development are genotype 1b ([@b16-btt-2-453]) and amino acid substitutions in the HCV core region ([@b2-btt-2-453]).

Importantly, coexistence of etiologies, eg, HBV and HCV infection, HBV infection, and aflatoxin B1 exposure (Yu and Yan 2004; [@b65-btt-2-453]), HBV or HCV infection and alcohol use or diabetes mellitus ([@b43-btt-2-453]), HCV infection and liver steatosis (Ohata et al 2004), environmental factors, eg, alcohol ([@b68-btt-2-453]; [@b105-btt-2-453]; [@b63-btt-2-453]), as well as diabetes mellitus, obesity, and tobacco use ([@b19-btt-2-453]; [@b18-btt-2-453]; [@b37-btt-2-453]; [@b63-btt-2-453]), has to be considered and further increases the relative risk of HCC development. Interestingly, coffee consumption appears to reduce the HCC risk ([@b9-btt-2-453]). HCC is generally more frequent in males than in females. Whether this is related to the protective effect of estrogens, as recently demonstrated in an animal model of chemical hepatocarcinogenesis ([@b71-btt-2-453]), remains to be determined.

HCC pathogenesis
================

Some of the steps involved in the molecular pathogenesis of HCC have been elucidated in recent years ([@b35-btt-2-453]). As for most types of cancer, hepatocarcinogenesis is a multistep process involving different genetic alterations that ultimately lead to malignant transformation of the hepatocyte. While significant progress has been made in recognizing the sequence of events involved in other forms of cancer, most notably in colorectal cancer and certain hematopoietic malignancies, the molecular contribution of the different factors and their interaction in hepatocarcinogenesis are still poorly understood. HCC is phenotypically (morphology, microscopy) and genetically very heterogenous, possibly in part due to the heterogeneity of etiologic factors implicated in HCC development, the complex functions of the liver cell, and the advanced stage at which HCC usually are becoming clinically symptomatic and diagnosed. Malignant transformation of hepatocytes may occur regardless of the etiologic agent through a pathway of increased liver cell turnover, induced by chronic liver injury and regeneration in a context of inflammation, immune response, and oxidative DNA damage. This may result in genetic alterations that cause activation of cellular oncogenes or inactivation of tumor suppressor genes ([@b30-btt-2-453]), possibly in cooperation with genomic instability, including DNA mismatch repair defects and impaired chromosomal segregation, overexpression of growth and angiogenic factors, and telomerase activation ([@b77-btt-2-453]; [@b10-btt-2-453]; [@b88-btt-2-453]; [@b94-btt-2-453]; [@b105-btt-2-453]). Further, epigenetic modifications, eg, aberrant methylation, seem also to be involved in the molecular pathogenesis of human HCC ([@b20-btt-2-453]). Chronic hepatitis B, C, and D, alcohol, metabolic liver diseases such as hemochromatosis and α-1-antitrypsin deficiency, as well as NAFLD may act predominantly through this pathway of chronic liver injury, regeneration, and cirrhosis. Since the vast majority of HCC (70%--90%) develop in a cirrhotic liver, liver cirrhosis is a major clinical risk factor for HCC development. Most HCC occur after many years or decades of chronic hepatitis that provides the mitogenic and mutagenic environment that induces random genetic alterations which eventually result in the malignant transformation of hepatocytes and HCC development. While there is evidence that HBV and possibly also HCV may under certain circumstances play an additional direct role in the molecular hepatocarcinogenesis, aflatoxins have been shown to induce mutations of the p53 tumor suppressor gene, thus pointing to the contribution of an environmental factor to tumor development at the molecular level. Further, in a transgenic mouse model it has been shown that chronic immune-mediated liver cell injury without environmental or infectious agents is sufficient to cause HCC ([@b69-btt-2-453], [@b70-btt-2-453]) and that inhibition of cytotoxic T lymphocyte-induced apoptosis and chronic inflammation by neutralization of the Fas ligand prevents HCC development in this model ([@b70-btt-2-453]). In addition, also in a transgenic mouse model it has been demonstrated that NF-kappa B may be the link between inflammation and HCC development ([@b5-btt-2-453]; [@b80-btt-2-453]). Finally, individual polymorphisms of drug metabolizing enzymes, eg, various cytochrome P450 oxidases, N-acetyltransferases, and glutathione-S-transferase, may contribute to the genetic susceptibility to HCC development ([@b24-btt-2-453]).

HCC staging
===========

For HCC staging, seven systems have been proposed that address the extent and prognosis of the disease ([@b28-btt-2-453]; Talwalker and Gores 2004): the Okuda staging system ([@b76-btt-2-453]), the TNM classification and its modification by the Union International Contre Cancer (UICC) ([@b54-btt-2-453]), the Barcelona Clinic Liver Cancer (BCLC) classification ([@b57-btt-2-453]), the Cancer of the Liver Italian Program (CLIP) score ([@b39-btt-2-453]), the Japan Integrated Staging (JIS) score ([@b52-btt-2-453]), the Groupe d'Etude de Traitement du Carcinoma Hepatocellulaire (GRETCH) score (Chevet et al 1999), and the Chinese University Prognostic Index (CUPI). The Okuda staging system is very effective for the identification of a subgroup of patients (Okuda III) with a very poor prognosis who should be treated with best supportive care (BSC) only. The BCLC classification appears especially useful for the selection of treatment options but has not been independently validated. The CLIP score was shown to be superior to the Okuda staging system but has not been systematically assessed in patients undergoing resection or liver transplantation. While a recent study indicates that the new prognostic JIS score is superior to the CLIP score ([@b52-btt-2-453]), a comparison of the staging systems in an American cohort revealed that the BCLC had the best independent predictive power ([@b62-btt-2-453]).

The natural course of the disease and the median survival of patients with HCC depend on the stage of the disease at the time of diagnosis. In patients with CLIP score 0 or Okuda stage I the median survival is in the range of 23--69 months, while in patients with CLIP score 3--5 or Okuda stage III median survival is only 1--14 months ([@b7-btt-2-453]). The staging system is clinically most important for the appropriate choice of the therapeutic strategy for individual patients. Cirrhotic patients developing a HCC during the last 5 years of surveillance survived longer than previously, due to improved management of the tumor and of the complications of cirrhosis ([@b87-btt-2-453]). Importantly, however, in a population-based study in the US underutilization of potentially curative therapies even among patients with favorable HCC features is a problem that needs to be addressed ([@b36-btt-2-453]).

Current therapeutic strategies for HCC
======================================

Current therapeutic strategies for HCC can be devided into established therapies such as surgical interventions (tumor resection and LTx), percutaneous interventions (ethanol injection, radiofrequency thermal ablation), transarterial interventions (embolization, chemoperfusion, or chemoembolization), and experimental strategies such as radiation therapy and drugs, including gene and immune therapy. Potentially curative therapies are tumor resection, LTx, and percutaneous interventions that can result in complete responses and improved survival in a high proportion of patients. In selected cases transarterial interventions result in palliation with, in some cases, good response rates and improved survival. Until recently, for patients with advanced HCCs no therapy was available that prolonged overall survival (OS), indicating the need for new targeted-therapies. In 2007 Sorafenib, a multikinase inhibitor, showed an increase of overall survival in patients with unresectable HCC. Besides this agent, various different molecules have been engineered that are currently tested in various tumors including HCC. These targeted therapies are reviewed below.

Potential targets for HCC therapies
===================================

Growth factors, their related receptors, and downstream signaling pathways play a major role in the development and maintenance of various cancers including HCC and are of significant interest for future therapeutic approaches. During fetal life, a large number of growth factors including the epidermal growth factor (EGF), insulin-like growth factors (IGFs), the hepatocyte growth factor (HGF), the vascular endothelial growth factor (VEGF), the fibroblast growth factor (FGF), the platelet-derived growth factor (PDGF), and the transforming growth factors-α and -β (TGF-α, TGF-β) are produced in the liver. Their secretion declines or shuts down in an adult liver; however, when liver regeneration is required after injury or damage ([@b29-btt-2-453]; [@b31-btt-2-453]), particularly growth factors such as EGF, TGF-α, IGFs, and VEGF can be upregulated by normal hepatocytes. This normally transient upregulation is dysregulated in the chronic injured liver leading to sustained mitogenic/oncogenic signaling, thereby playing an important role in hepatocarcinogenesis.

Furthermore, members of the FGF and PDGF families play important roles in promoting liver fibrosis and HCC growth ([@b73-btt-2-453]; [@b21-btt-2-453]). Like HGF, these growth factors are produced and released from non-hepatocyte sources such as activated hepatic stellate cells, myofibroblasts, endothelial cells, Kupffer cells, and bile duct epithelia and do also contribute to hepatocarcinogenesis.

Among the most critical cellular signaling pathways that support hepatocarcinogenesis are the receptor tyrosine kinase-activated pathways which include the rat sarcoma/rat sarcoma-activated factor (raf)/mitogen activated protein kinase/extracellular regulated kinase kinase/extracellular regulated kinase pathway (Ras/Raf/MEK/ERK), the Janus kinase/signal tranducers and activator of transcription pathway (JAK/STAT)s, and the phosphatidylinositide 3 kinase/protein kinase B (AKT)/mammilian target of rapamycin pathway (PI3K/AKT/mTOR) ([@b46-btt-2-453]; [@b106-btt-2-453]).

These factors represent potential therapeutic targets in HCC treatment ([Table 2](#t2-btt-2-453){ref-type="table"}). A selection of agents currently in the development and/or testing stages for the clinical application in targeted HCC treatment is summarized in the following section.

Anti-EGFR therapies
===================

The expression of several EGF family members, specifically EGF, TGF-α, and heparin binding-EGF, as well as the EGFR, has been described in several HCC cell lines and in tissue. Multiple strategies to target EGFR signaling pathways have been developed, and two classes of anti-EGFR agents display antitumor activity in cancer: monoclonal antibodies (eg, cetuximab), which competitively inhibit extracellular endogenous ligand binding, and small molecules, which inhibit the intracellular TK domain (eg, gefitinib, erlotinib).

While in vitro and in vivo studies with these agents have been shown to inhibit proliferation of HCC and metastasis formation, only a few clinical studies have been conducted so far. Two phase 2 clinical studies have evaluated the safety and efficacy of erlotinib given at a dose of 150 mg daily in patients with advanced HCC. In the study by [@b79-btt-2-453], 39% of patients had a partial response, and 32 had stable disease at 6 months. Median OS was 13 months. In a study by [@b97-btt-2-453], 43% of patients achieved progression-free survival (PFS) at 16 weeks. Median OS was 25.0 weeks. Another compound, gefitinib, given at 250 mg daily was examined in a single-arm phase 2 study. Thirty-one patients were recruited for the study (O'Dwyer et al 2006). One patient had a partial response, and 7 patients had stable disease. Median PFS was 2.8 months, and the median OS was 6.5 months. Lapatinib, a selective dual inhibitor of both EGFR and HER-2/NEU TKs, also demonstrated modest activity in HCC in a preliminary report ([@b83-btt-2-453]).

Cetuximab was tested in two studies in patients with advanced HCC. [@b107-btt-2-453] enrolled 30 patients with advanced HCC. Five patients had stable disease, median OS was 9.6 months, and the median PFS was 1.4 months. [@b42-btt-2-453] reported their experience of cetuximab in a similarly designed study and observed no responses in 27 patients; the median time to progression for all patients was 8 weeks.

The combination of cetuximab with GEMOX was evaluated in a phase 2 study ([@b60-btt-2-453]). Forty-three patients were enrolled and 35 patients were available for efficacy analysis with a response rate of 23%.

Currently, further anti-EGFR-based approaches are being tested in clinical trials, especially in combination with either conventional cytostatics or with other targeted agents (Heuther et al 2005a, b; [@b67-btt-2-453]; [@b8-btt-2-453]) in order to block several carcinogenic pathways.

Antivascular endothelial growth factor/vascular endothelial growth factor receptor agents
=========================================================================================

HCCs are tumors with high vascular architecture. VEGF is a key factor in tumor angiogenesis and high levels of VEGF have been associated with the HCC grade and clinically with inferior OS ([@b23-btt-2-453]; [@b49-btt-2-453]; [@b82-btt-2-453]). Therefore, the inhibition of angiogenesis represents a potential and promising therapeutic target in HCC. Bevacizumab, a humanized murine monoclonal anti-VEGF antibody, alone or in combination with standard chemotherapy has become standard treatment in several human cancers (eg, colon cancer). Studies with bevacizumab monotherapy and in combination with other agents have been performed in patients with advanced HCC. Most of the trials were phase 2 studies with encouraging results for PFS and OS. Of interest is the study by [@b97-btt-2-453]. In this phase 2 study, bevacizumab at a dose of 10 mg/kg intravenously once every 14 days and erlotinib at a dose of 150 mg orally daily was given to patients with advanced HCC ([@b97-btt-2-453]). Thirty-four patients were eligible for the efficancy analysis: 1 patient had a confirmed complete response (CR), and 6 patients had a partial response (PR), for a 21% response rate. Median PFS was 9 months, and median OS 19 months. However, these promising results have to be confirmed in a randomized controlled study.

In terms of safety and tolerability, despite the initial safety concerns for bevacizumab use in patients with liver cirrhosis and portal hypertension, in particular the risks for gastrointestinal bleeding and thrombosis, the most common bevacizumab-related side effects were hypertension, bleeding, and proteinuria, that were generally well managed ([@b89-btt-2-453]).

In addition, several agents that inhibit the tyrosine kinase activity of VEGFR have been synthesized. PTK787/ZK222584 (vatalanib) is an oral angiogenesis inhibitor that targets all known VEGFR TKs. In an open-labeled, multicenter, phase 1 study the safety, tolerability, and pharmacokinetic profile of PTK787 with a daily dose between 750 mg to 1250 mg was analyzed in patients with unresectable HCC ([@b51-btt-2-453]). 750 mg daily was defined as maximal tolerated dose; however, in terms of efficacy no complete response or partial response was observed. Fifty percent of the analyzed patients had stable disease and 50% had progressive disease.

Another potent, oral, pan-VEGFR TK inhibitor with activity against PDGFRs and c-Kit is AZD2171 (cediranib). So far, one phase 2 study by [@b3-btt-2-453] has studied the administration of AZD2171 (45 mg daily for a 28-day treatment cycle) in patients with advanced HCC. In terms of toxicity, 84% developed grade 3 toxicity mainly fatigue, hypertension, and anorexia.

A further encouraging approach is the use of dual-targeting tyrosine kinase inhibitors, such as NVP-AEE788 or zactima (ZD6474). These molecules target both the VEGFRs and the EGFR. Recently, in in vivo studies of non-HCC tumor models (eg, colon, cholangiocarcinoma, NSCLC), NVP-AEE788 showed significant antitumor efficacy based on the inhibition of tumor cell proliferation by blocking hepatoma EGFR and angiogenesis by blocking endothelial VEGFR. Nevertheless, an evaluation of this interesting observation in clinical trials is warranted ([@b45-btt-2-453]; [@b17-btt-2-453]; [@b100-btt-2-453]; [@b104-btt-2-453].

Multi-kinase inhibition
=======================

Hepatocarcinogenesis is a complex process involving various, diverse signaling pathways. Therefore, molecularly targeted agents that interact with multiple signaling pathways/effectors appear to be very attractive in the treatment of patients with HCC. The novel bi-aryl urea sorafenib (Nexavar^®^), an orally available multi-kinase inhibitor, targets kinases of wild-type B-Raf, mutant V559EB-Raf and C-Raf, thereby blocking tumor growth. In addition, sorafenib inhibits receptor tyrosine kinases involved in angiogenesis, including human VEGF receptors-2 and -3 (VEGFR-2/-3) and PDGF-βR.

Sorafenib has been tested for the treatment of advanced HCC. In a phase 2 trial 137 patients with advanced, inoperable HCC, sorafenib (400 mg bid) induced a partial response in 2.2%, a minor response in 5.8% and a stable disease (SD) in 34% of patients ([@b1-btt-2-453]). The median time to progression (TTP) was 4.2 months, and the median OS was 9.2 months. Sorafenib was fairly well tolerated. Grade 3 and 4 drug-related toxicities were fatigue (9.5%), diarrhea (8%), and hand-foot skin reaction (5.1%). Interestingly, in an analysis of a subgroup of treated patients (n = 33), pretreatment tumor phosphorylated ERK (pERK) levels were correlated with the TTP. Patients with an intense pERK staining in their tumors survived longer, suggesting that inhibition of the Raf/MEK/ERK pathway is central to sorafenib's mode of anti-tumor action in HCC ([@b40-btt-2-453]). Whether this generally holds true for HCC remains to be determined. In other tumor entities the antineoplastic potency of sorafenib appears to be mainly due to its antiangiogenic activity ([@b101-btt-2-453]; [@b55-btt-2-453]).

Based on the encouraging, positive results of this phase 2 trial, a randomized, double-blinded, phase 3 trial with 602 patients with advanced HCC was initiated. An evaluation of this international study (Sorafenib HCC Assessment Randomized Protocol \[SHARP\]) led to discontinuation, as the HCC patients treated with sorafenib achieved a significant survival benefit over the placebo-treated controls. The data of the analysis were presented at the ASCO meeting in 2007 and showed that median OS in the sorafenib-treated arm was 10.7 months vs 7.9 months in the control arm ([@b56-btt-2-453]). Of note, the median TTP was 5.5 months in the sorafenib arm vs 2.8 months in the control arm. The toxicity profile of this trial was comparable with that of the phase 2 trial. Based on these findings, sorafenib represents the first agent that has shown improved OS benefits in patients with advanced HCC and has recently gained accelerated approval by the FDA for the treatment of advanced unresectable HCC.

Another interesting multikinase inhibitor is sunitinib (Sutent^®^). It is a small molecule that inhibits members of the split-kinase domain family of receptor TKs (RTKs) including VEGFR types 1 and 2 (fms-related TK 1 \[FLT1\] and the FLK1 kinase insert domain receptor \[FLK1/KDR\]); PDGFR-α and PDGFR-β, the stem cell factor receptor c-KIT, and the *FLT3* and *RET* kinases ([@b78-btt-2-453]; [@b64-btt-2-453]; [@b4-btt-2-453]). In vitro studies with various tumor cell lines have shown that the antiangiogenic effects of sunitinib are mediated through VEGFR and PDGFR. Clinically, sunitinib has good oral bioavailability and is approved for the treatment of renal cell carcinoma and gastrointestinal stromal tumor.

Two independent phase 2 studies have examined the tolerability and efficacy of sunitinib in patients with advanced HCC. In the study by [@b107-btt-2-453] patients with advanced HCC received sunitinib 37.5 mg once daily on a standard 4-weeks-on/2-weeks-off regimen (6-week cycle). PFS was the primary endpoint. Median PFS in this trial was 4.1 months. A total of 26 patients were enrolled. Adverse events generally were manageable, and the most common adverse events included neutropenia, lymphopenia, thrombocytopenia, elevation of transaminases, fatigue, and skin rash. In the other phase 2 study, sunitinib was administered at a dose of 50 mg daily in a 4-weeks-on/2-weeks-off regimen to patients with unresectable HCC ([@b38-btt-2-453]). The primary endpoint of the study was the overall response rate according to RECIST criteria. Thirty-seven patients entered the trial, 1 patient had a confirmed PR, and 39% of patients had SD. Grade 3 and 4 toxicities included thrombocytopenia (43%), neutropenia (24%), central nervous system symptoms (24%), asthenia (22%), and hemorrhage (14%). Of interest, in a significant number of patients sunitinib led to tumor necrosis in both studies; however, whether tumor necrosis is indeed correlated with clinical efficacy remain to be defined in future studies.

mTOR inhibition
===============

In vitro as well as preclinical in vivo data of HCC show that mTOR inhibition by rapamycin and its analogues (the cell cycle inhibitor-779 \[CCI-779, temsirolimus\], RAD001 \[everolimus\]) an orally bioavailable derivative of rapamycin, AP23573) significantly reduces HCC growth and improves survival primarily via antiangiogenic effects ([@b86-btt-2-453]). A phase 2/3 trial evaluating everolimus for advanced HCC is currently starting to recruit patients ([@b85-btt-2-453]) (NIH, NCT00390195). In addition, the combination treatment of rapamycin and its analalogues with conventional cytostatic drugs (eg, doxorubicin, vinblastine) has been shown to enhance the antitumoral potency compared with monotherapy with either doxorubicin or vinblastine in patients with HCC ([@b84-btt-2-453]; [@b90-btt-2-453]; [@b92-btt-2-453]). Therefore, the in vitro and in vivo data from other tumor entities suggest that mTOR inhibitors, including the rapamycin analogues CCI-779, RAD001 and AP23573, are promising combination agents for future cancer therapy.

Proteasome inhibition
=====================

Bortezomib (Velcade^®^) is a proteasome inhibitor, which blocks multi-ubiquitinated protein degradation by reversibly and competitively inhibiting the active site threonine residue of the 26S proteasome ([@b66-btt-2-453]). Antineoplastic activity of bortezomib has already beeen shown in several in vitro and in vivo studies ([@b11-btt-2-453]; [@b6-btt-2-453]; [@b46-btt-2-453]) and has been recently approved for the treatment of mantle cell lymphoma. A phase 1/2 trial of bortezomib in patients with advanced HCC showed disease stabilization in some patients with good tolerability. In this study the authors recommend evaluating combination treatment strategies using bortezomib together with HCC-relevant cytostatics such as doxorubicin ([@b44-btt-2-453]).

Conclusion
==========

Agents that specifically target key molecules in carcinogenesis have emerged over the last decade. Of major interest are the growth factors and their receptors as well as their signaling pathways. The molecular targeting of these factors has become a promising approach for the effective treatment of various cancers, including hepatocellular carcinoma. The recent in vitro and in vivo findings as well as the clinical trials clearly demonstrate that advanced HCC is no longer a tumor without specific medical treatment options. Sorafenib, a multi-kinase inhibitor, is the first medication that is now approved for the treatment of patients with advanced HCC. However, several other promising new drugs are currently under investigation. Most probably, the combination of agents with different molecular targets as the growth factor receptor inhibitors, proteasome inhibitors, or cytostatics will improve the clinical response in patients with advanced HCC with tolerable and manageable side effects. Furthermore, the use of targeted therapies such as sorafenib, that are already approved for therapy in advanced HCC, might also improve HCC recurrence in patients who undergo resection, local ablation and transarterial chemoembolization, which is currently being tested in several studies.
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###### 

Major hepatocellular carcinoma etiologies

  -------------------------------------------------------------------------------------
  Chronic hepatitis B, C, and D
  Toxins (eg, alcohol, tobacco, aflatoxins)
  Hereditary metabolic liver diseases (eg, hereditary hemochromatosis,
  α-1-antitrypsin deficiency)
  Autoimmune hepatitis
  States of insulin resistance
    Overweight in males
    Diabetes mellitus
    Non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD)
  -------------------------------------------------------------------------------------

###### 

Selection of agents for targeted therapy in hepatocellular carcinoma

  Name          Target                       Current status
  ------------- ---------------------------- ---------------------------------------------------------------------
  Gefitinib     EGFR                         phase 2 study ([@b72-btt-2-453])
  Erlotinib     EGFR                         phase 2 study ([@b79-btt-2-453]; [@b97-btt-2-453])
  Lapatanib     EGFR                         phase 2 study ([@b83-btt-2-453])
  Cetuximab     EGFR                         phase 2 study ([@b42-btt-2-453][@b56-btt-2-453]; [@b107-btt-2-453])
  Bevacizumab   VEGF                         phase 1/2 study (Schartz et al 2006 [@b97-btt-2-453])
  Sorafenib     c-Raf1, B-Raf, VEGFR PDGFR   phase 3 study ([@b56-btt-2-453])
  Sunitinib     PDGFR, VEGFR, c-KIT, FLT-3   phase 2 study ([@b38-btt-2-453]; [@b107-btt-2-453])
  Vatalanib     VEGFR, PDGFR, c-KIT          phase 1 study ([@b51-btt-2-453])
  Cediranib     VEGFR                        phase 2 study ([@b3-btt-2-453])
  Rapamycin     mTOR                         phase 1/2 study ([@b86-btt-2-453]; [@b85-btt-2-453])
  Everolimus    mTOR                         phase 1/2 study ([@b86-btt-2-453]; [@b85-btt-2-453])
  Bortezomib    proteasome                   Phase 1/2 study ([@b44-btt-2-453])
